Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Larimar Therapeutics Inc (LRMR)

Larimar Therapeutics Inc (LRMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Larimar Therapeutics Inc THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 USA

https://larimartx.com Employees: 42 P: 844-511-9056

Description:

Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.

Key Statistics

Overview:

Market Capitalization, $K 387,947
Enterprise Value, $K 361,197
Shares Outstanding, K 63,807
Annual Sales, $ 0 K
Annual Net Income, $ -36,950 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -15,500 K
EBIT, $ -73,750 K
EBITDA, $ -75,280 K
60-Month Beta 0.95
% of Insider Shareholders 3.50%
% of Institutional Shareholders 91.92%
Float, K 61,574
% Float 96.50%
Short Volume Ratio 0.66

Growth:

1-Year Return 99.03%
3-Year Return -39.92%
5-Year Return -37.45%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 96.32%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.24 on 10/30/24
Next Earnings Date 11/12/24
Earnings Per Share ttm -1.15
EPS Growth vs. Prev Qtr 29.41%
EPS Growth vs. Prev Year -14.29%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-12 on 05/29/20

LRMR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -35.87%
Return-on-Assets % -32.37%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.05
Book Value/Share 3.11
Interest Coverage -1.62
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar